BHBenjamin Hendricks

Benjamin Hendricks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin Hendricks has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Magnetic Resonance–Guided Laser Interstitial Thermal Therapy for Recurrent Glioblastoma and Radiation Necrosis: A Single-Surgeon Case Series

    by Jubran H. Jubran, Lea Scherschinski, Nikhil Dholaria, Kelly A. Shaftel, Dara S. Farhadi, Femi C. Oladokun, Benjamin K. Hendricks, Kris A. Smith


  • Open Access

    E-140 Morphological differences of ruptured versus unruptured wide neck aneurysms: insights from the everrun registry

    by T Hardigan, B Hendricks, J Yoon, C Kellner, M Lawton, J Mocco, J Mascitelli

    Introduction Wide neck aneurysms (WNAs) have classically been defined as having a neck width greater than 4 mm (N>4) and/or dome-to-neck ratio less than 2 (DTNR4, DTNRResults The analysis included 310 WNA (87 Rvs. 223 U). There was a female preponderance in both groups without significant difference (R: 80.5%, U: 75.8%). Ruptured WNA had significantly smaller neck size(R: 3.72±1.39 mm, U: 4.5±1.78mm) and dome width (R: 5.04±2.39mm, U: 6.29±3.37 mm)(pConclusions The most novel finding in this subsequent analysis is that ruptured WNAs tend to be smaller with unfavorable DTNR whereas unruptured WNAs tend to be larger with a favorable DTNR. Higher rates of Pcomm/Acomm location in the ruptured WNA cohort are consistent with previous studies of all aneurysms and the significant racial disparity in ruptured vs. unruptured WNAs highlight the need for further characterization of both the biological and societal risks that may underlie these results. Disclosures T. Hardigan: 1; C; Neurosurgery Research and Education Foundation Fellowship. 2; C; Telos. B. Hendricks: 2; C; Medtronic. J. Yoon: None. C. Kellner: 1; C; Penumbra, Siemens. M. Lawton: 2; C; Zeiss, Aesculap. 6; C; Mizuho. J. Mocco: 1; C; Stryker, Microvention, Penumbra. 2; C; Cerebrotech, Viseon, Endostream, Vastrax, RIST, Synchron, Viz.ai, Perflow, CV Aid. 4; C; Cerebrotech, Imperative Care, Endostream, Viseon, BlinkTBI, Myra Medical, Serenity, Vastrax, NTI, RIST, Viz.ai, Synchron, Radical, Truvic. J. Mascitelli: None.

  • Open Access

    E-147 Treatment differences of ruptured versus unruptured wide neck aneurysms: insights from the everrun registry

    by T Hardigan, B Hendricks, J Yoon, C Kellner, M Lawton, J Mocco, J Mascitelli

    Introduction Wide neck aneurysms (WNAs) are more challenging to treat compared to narrowneck aneurysms, requiring more advanced techniques. The Wide Neck/EVERRUN Registry compared endovascular versus microsurgical techniques for both unruptured and ruptured aneurysms. Purpose To utilize a previously collected multicenter WNA registry and compare treatment strategy (EVT vs. MS) and angiographic results in ruptured vs. unruptured WNAs. Methods WNAs included in this registry were saccular and not previously treated. WNA definition was aneurysm neck greater than or equal to 4 mm or dome-to-neck-ratio (DTNR) less than 2. Differences in treatment strategy (EVT vs. MS) and angiographic results were the primary outcomes of the study. The angiographic outcome was assessed immediately following treatment and again at last follow-up using the Raymond scale with core lab review (adequate occlusion: RR 1-2). Statistical significance was set at an alpha level of pResults The analysis included 310 WNA (87 ruptured (R) aneurysms vs. 223 unruptured (U)). There were no significant differences in the rate of EVT vs. MS between ruptured (R) vs. unruptured (U) aneurysms (Clipping, R: 36.8%, U: 37.7%). Amongst EVT, ruptured WNA were more commonly treated with stand-alone coiling (R: 27.6%, U: 5.8%) and balloon-assisted coiling (R: 32.2%, U: 10.8%) and unruptured aneurysms were more commonly treated with flow diversion (R: 1.1%, U: 22.9%) and stent-assisted coiling (R: 2.3%, U: 21.5%)(pConclusions When treating WNAs, rupture status significantly influences the EVT choice, likely based on the need for dual antiplatelet therapy. The discrepancy in initial adequate occlusion in the unruptured cohort is likely due to the higher use of flow diverters. Ruptured WNAs were more difficult to treat as evidenced by higher rates of retreatment and procedural complications, however this did not impact the final angiographic outcomes. Disclosures T. Hardigan: 1; C; Neurosurgery Research and Education Foundation Fellowship. 2; C; Telos. B. Hendricks: 2; C; Medtronic. J. Yoon: None. C. Kellner: 1; C; Penumbra, Siemens. M. Lawton: 2; C; Zeiss, Aesculap. 6; C; Mizuho. J. Mocco: 1; C; Stryker, Microvention, Penumbra. 2; C; Cerebrotech, Viseon, Endostream, Vastrax, RIST, Synchron, Viz.ai, Perflow, CV Aid. 4; C; Cerebrotech, Imperative Care, Endostream, Viseon, BlinkTBI, Myra Medical, Serenity, Vastrax, NTI, RIST, Viz.ai, Synchron, Radical, Truvic. J. Mascitelli: None.

  • Open Access

    Magnetic Resonance-Guided Laser Interstitial Thermal Therapy for Management of Low-Grade Gliomas and Radiation Necrosis: A Single-Institution Case Series

    by Lea Scherschinski, Jubran H. Jubran, Kelly A. Shaftel, Charuta G. Furey, Dara S. Farhadi, Dimitri Benner, Benjamin K. Hendricks, Kris A. Smith

    Background: Laser interstitial thermal therapy (LITT) has emerged as a minimally invasive treatment modality for ablation of low-grade glioma (LGG) and radiation necrosis (RN). Objective: To evaluate the efficacy, safety, and survival outcomes of patients with radiographically presumed recurrent or newly diagnosed LGG and RN treated with LITT. Methods: The neuro-oncological database of a quaternary center was reviewed for all patients who underwent LITT for management of LGG between 1 January 2013 and 31 December 2020. Clinical data including demographics, lesion characteristics, and clinical and radiographic outcomes were collected. Kaplan–Meier analyses comprised overall survival (OS) and progression-free survival (PFS). Results: Nine patients (7 men, 2 women; mean [SD] age 50 [16] years) were included. Patients underwent LITT at a mean (SD) of 11.6 (8.5) years after diagnosis. Two (22%) patients had new lesions on radiographic imaging without prior treatment. In the other 7 patients, all (78%) had surgical resection, 6 (67%) had intensity-modulated radiation therapy and chemotherapy, respectively, and 4 (44%) had stereotactic radiosurgery. Two (22%) patients had lesions that were wild-type IDH1 status. Volumetric assessment of preoperative T1-weighted contrast-enhancing and T2-weighted fluid-attenuated inversion recovery (FLAIR) sequences yielded mean (SD) lesion volumes of 4.1 (6.5) cm3 and 26.7 (27.9) cm3, respectively. Three (33%) patients had evidence of radiographic progression after LITT. The pooled median (IQR) PFS for the cohort was 52 (56) months, median (IQR) OS after diagnosis was 183 (72) months, and median (IQR) OS after LITT was 52 (60) months. At the time of the study, 2 (22%) patients were deceased. Conclusions: LITT is a safe and effective treatment option for management of LGG and RN, however, there may be increased risk of permanent complications with treatment of deep-seated subcortical lesions.


  • Open Access

    Ketogenic Metabolic Therapy for Glioma

    by Kris A Smith, Benjamin K. Hendricks, Joseph D. DiDomenico, Beth N. Conway, Tracy L. Smith, Amir Azadi, Ekokobe Fonkem

    Purpose: This study describes a retrospective case series of patients with glioma who received ketogenic metabolic therapy through dietary adherence and intermittent fasting. Methods: A retrospective chart review of a single surgeon’s clinic records was performed to identify patients who maintained nutritional ketosis for at least four months between January 2015 and October 2020. Results: Sixteen patients who met the inclusion criteria constituted a heterogeneous population of patients with diagnoses including eight World Health Organization (WHO) grade IV gliomas (seven glioblastoma, one gliosarcoma), seven WHO grade III gliomas (three oligodendroglioma, four astrocytoma), and one WHO grade II oligodendroglioma. IDH1 mutation status was present for 12 patients, and MGMT methylation status was present for eight patients. The mean (standard deviation [SD]) duration of ketogenic metabolic therapy was 20.6 (13.8) months. The Response Assessment in Neuro-oncology Criteria was applied during the ketogenic metabolic therapy interval, indicating a complete response in eight patients and partial response in eight patients. The mean (SD) progression-free survival while patients maintained ketogenic metabolic therapy was 20.0 (14.4) months. Conclusion: Ketogenic metabolic therapy appears to convey a survival advantage within this patient series, which highlights the possibility that this therapy, when strictly applied, can augment the standard of care. Further exploration of this modality in a prospective series is warranted to formally explore this therapy.


  • Open Access

    Unique Presentation and Novel Surgical Approach to a Transcribriform Penetrating Head Injury Caused by a Nail Gun

    by Benjamin K. Hendricks, Joseph D. DiDomenico, Michael T. Lawton, Andrew S. Little

    A penetrating head injury caused by a nail gun is an infrequent clinically diverse condition that varies in severity by the neurovascular structures involved. The authors present the case of a patient whose frontal lobe was pierced by a nail that entered via a transnasal transcribriform trajectory without causing vascular injury or intracranial hemorrhage; the man was unaware of the nail’s presence and presented with headache five days after the incident. The nail was extracted using a bifrontal craniotomy for direct visualization and for defect repair of the skull base combined with endoscopic endonasal extraction of the nail.


  • ZAP-X Gyroscopic Radiosurgery System: A Preliminary Analysis of Clinical Applications within a Retrospective Case Series

    by Benjamin K. Hendricks, Joseph D. DiDomenico, Igor J. Barani, F. David Barranco

    Introduction: The ZAP-X Gyroscopic Radiosurgery system (ZAP Surgical Systems, Inc., San Carlos, CA, USA) is a novel high-dose targeted stereotactic radiosurgery platform for outpatient use that includes self-shielding, X-ray image guidance, and the capacity to aim the radiation beam gyroscopically at an intracranial lesion using 5 independent degrees of freedom. The ZAP-X Gyroscopic Radiosurgery system accomplishes these actions while meeting widely accepted standards for dose gradient and accuracy. This retrospective study examined data of patients treated with gyroscopic radiosurgery (GRS) to document clinical outcomes. Methods: Medical records of all outpatients treated with GRS over a 20-month period from January 2019 to August 2020 were searched to extract relevant details, including follow-up data until August 2021 (32-month study interval). Patients with Results: Sixty-eight patients received outpatient treatment with GRS during the 20-month treatment interval, with 59 patients remaining after exclusion for the minimum follow-up threshold, with a mean (standard deviation [SD]) fractionation of 1.85 (1.63). Eighty-two lesions were treated across a very heterogeneous patient population, including meningiomas (42.4%), metastases (39.0%), gliomas (6.8%), schwannomas (1.7%), and pituitary tumor (1.7%). Mean (SD) radiographical follow-up data (14.7 [6.60] months) were available for 56 patients. During that interval, 13 treated lesions in 13 patients (15.9%) demonstrated progression, 9 of which were stable during the initial posttreatment imaging surveillance period. Mean lesion volume was stable from pretreatment (2.54 cm3 [4.37 cm3]) to most recent follow-up (2.80 cm3 [8.20 cm3]) (t [79] = −0.310; p = 0.76). Minor adverse clinical events were noted in 3 (5.1%) of the 59 patients during the posttreatment phase that may have been related to the treatment. Ten (16.9%) patients died within the 32-month study interval. Discussion/Conclusion: This preliminary assessment of the first series of patients treated with the Zap-X Gyroscopic Radiosurgery system documents its overall feasibility in clinical applications. Although the duration of follow-up was brief, GRS appeared to be both safe and effective. Additional analysis, with an ongoing prospective registry, is underway.


  • Eponyms in Vascular Neurosurgery: Comprehensive Review of 18 Veins

    by Dimitri Benner, Benjamin K. Hendricks, Arnau Benet, Michael T. Lawton


  • Open Access

    Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms

    by J.-K. Burkhardt, V. Srinivasan, A. Srivatsan, F. Albuquerque, A.F. Ducruet, B. Hendricks, B.A. Gross, B.T. Jankowitz, A.J. Thomas, C.S. Ogilvy, et al.

    BACKGROUND AND PURPOSE: The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. MATERIALS AND METHODS: On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. RESULTS: Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (P < .0001) and rupture status during treatment (P = .03). CONCLUSIONS: This multicenter analysis provides a real-world safety and efficacy profile for the treatment of intracranial aneurysms with the Neuroform Atlas stent.